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Aberrant Mineralization in PXE
Targeted disruption of the Abcc6 gene in 
mouse models for pseudoxanthoma elas-
ticum (PXE) resulted in mineralization of 
the soft tissues, including skin. Jiang and 
co-workers examined the Abcc6-/- mouse 
with respect to the fetuin-A, MGP, and Ank 
proteins, as well as alkaline phosphatase 
activity, all of which inhibit mineraliza-
tion. Fetuin-A is clearly expressed in the 
liver and subsequently transported in the 
circulation to aberrant mineralization sites, 
where it co-localizes with mineral deposits 
in connective tissue. If the reduced fetuin-A 
levels do play a pathomechanistic role in ectopic mineralization of connective tissues 
in PXE, intravenous protein therapy might halt—and even reverse—mineralization. 
See page 1392
Cracking Knuckle Pads
GJB2 mutations in the connexin26 peptide are the 
major cause of autosomal nonsyndromic congeni-
tal sensorineural hearing loss (SNHL), and connex-
in26 mutations have been identified in SNHL with 
palmoplantar keratoderma (PPK). Akiyama and co-
workers encountered a 12-year-old Japanese boy with 
PPK, knuckle pads on all fingers, and severe SNHL. 
Cumulative data from this case and three prior cases 
suggest that alterations of the amino acid residues 
asparagine 54 and glycine 59 in connexin26 might 
be associated with knuckle pads, although there is 
no supportive etiologic evidence. Additional cases 
will be necessary to conclude that this mutation caused knuckle pads. See page 1540 
Substance P and AA
Siebenhaar and colleagues studied the 
expression and effects of substance 
P (SP) on immune cells in C3H/HeJ 
mice affected by alopecia areata (AA). 
During early stages of AA development, 
SP-immunoreactive nerve fibers in skin 
increased compared with nonaffected 
mice; but in advanced stages of AA, SP-
immunoreactive nerves and SP protein 
levels in skin decreased and SP degrad-
ing-enzyme expression increased com-
pared with control skin. Pharmacologic 
and genetic approaches will further 
clarify the role of SP and other neuropeptides in the pathobiology of autoimmune 
responses to hair-follicle antigens, which may result in new therapies for AA and other 
autoimmune disorders. See page 1489
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BRAF Mutations 
in Sebaceous 
Hyperplasias
MYH-associated polyposis 
(MAP) is characterized 
by multiple colorectal 
adenomas and cancer. Ponti 
et al. hypothesized that 
sebaceous lesions might 
be associated with genetic 
changes. They found BRAF 
mutations in the early 
phases of skin tumorigenesis 
in melanocytic and 
nonmelanocytic cutaneous 
neoplasms, suggesting that 
endoscopic and biomolecular 
screening may be a new way 
to detect MAP. See page 1387 
Enhanced Antigen 
Cross-Presentation 
with Colchicine
Colchicine (COL), a 
microtubule depolymerizing 
drug, is used for the 
treatment of many 
inflammatory skin diseases. 
Mizumoto et al. reported that 
COL-treated bone marrow–
derived dendritic cells have 
increased ability to cross-
present ovalbumin proteins 
to CD8 T cells isolated 
from transgenic mice. COL 
also promoted phenotypic 
maturation and cytokine/
chemokine production 
by human DCs. This study 
suggests a previously 
unrecognized pharmacologic 
activity of COL that should 
be considered when 
administering COL to 
patients with inflammatory 
skin disorders. See page 1543
